This is a multicenter, randomized, double-blind, placebo-controlled, parallel study.
The study participants include healthy male volunteers, ages 18 to 45. The patients will be divided into two therapy groups: the first group will take the investigational drug, while the second group will be given a placebo. Currently, the enrollment of patients for the study is significantly ahead of the planned schedule.
OCT team is responsible for site-management, project management, logistics and quality assurance.